Andson Biotech · May 2026
Company says it will exhibit at ASMS 2026 and showcase DynaChip X1 for automated native mass spectrometry and charge detection mass spectrometry.
Empowering Mass Spec for Biotech and Beyond
Company research
Public company, workplace, funding, and market signals
Overview
Atlanta-based biotools company building a microfluidic mass-spectrometry sample-preparation platform for biopharma and biotherapeutics.
Primary product
DynaChip X1
Founded
2021
Headquarters
Atlanta, Georgia, United States
Team size
11-50 employees
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
Mass spectrometry biotools / sample-preparation instrumentation
Offices
1705 Commerce Dr NW, Atlanta, Georgia 30318, United States
Atlanta, Georgia, United States
Business model
B2B scientific instrument sales
software-enabled hardware platform
Funding
Stage
Seed stage
Total raised
$8.9M
Latest round
Venture Round · Oct 2025
Latest amount
$4.7M
People & investors
Leadership
Mason Chilmonczyk, PhD
Co-Founder and CEO
Co-Founder and Board Member
Executive Chairman
President and Chief Commercial Officer
Vice President of Marketing and Business Development
Vice President of Operations
Senior Scientist
Work & culture
Mission-driven and science-forward startup culture that emphasizes innovation, bold execution, results, and high ownership. Hiring materials stress independence, fast shipping, and close collaboration across hardware, software, and operations.
Work style
Onsite
Compensation
Public job postings show full-time compensation around $80K-$150K plus 0.01%-1.0% equity for software roles, $65K-$115K plus equity for an electro-mechanical role, and $25/hour for an internship. Postings require US citizenship or visa eligibility, but no explicit sponsorship policy is published.
Product & market
Differentiators
- —Microfluidic sample-preparation platform for mass spectrometry
- —Vendor-agnostic interface that integrates with existing mass spectrometers
- —Automated rapid online buffer exchange and desalting workflows
- —Active interference removal for salts, metabolites, and detergents
- —Designed for native MS and CDMS use cases
- —Public materials claim up to 100x workflow productivity improvements
Technology
microfluidics
mass spectrometry
React
Python
FastAPI
embedded C++
SQL
Linux
nginx
TypeScript
Tailwind CSS
Figma
WebSockets
Arduino
PLC control
I2C
CAN
Ethernet
Modbus
GPIO
Customers
Pharmaceutical companies
Biopharma research teams
Biotherapeutics developers
Cell and gene therapy teams
Biologics researchers
Mass spectrometry labs
Scale & contact
Estimated revenue
≈$1.8M estimated ARR (2024)
Estimated monthly visits
2.9K
Traffic estimate as of Feb 2026
Latest news
Andson Biotech · Apr 2026
Company announced participation in IBBI 2026 and presentation of DynaChip X1 applications for biomolecular interactions and structural biology.
Andson Biotech · Mar 2026
Company said it would attend and present at the Oxford native MS symposium, highlighting the DynaChip X1 platform.
Georgia Tech News · Mar 2026
Georgia Tech profile on Mason Chilmonczyk and Andson Biotech describing the company as a commercialization of breakthrough research that simplifies development and production of cell and gene therapies.
Andson Biotech · Oct 2025
Official company announcement of a $4.7M round plus a $300K NIH SBIR Phase 1 grant to support commercial expansion and new product development.
Jobs and careers at Andson Biotech
0 jobs at Andson Biotech
No open positions
Check back later for new openings